openPR Logo

Press Releases from Marinomed Biotech AG (2 total)

Marinomed extends the range of Marinosolv applications

o Preclinical studies show promising results with new compounds like mometasone, fluticasone and fluorometholone o Potential for developments in allergy, asthma, and ophthalmology o Marinosolv facilitates the combination of active ingredients Vienna (Austria), March 9th 2020. Marinomed Biotech AG, a globally active biopharmaceutical company based in Vienna, has achieved promising results for further areas of application with its Marinosolv technology platform in preclinical studies. In addition to the lead products Budesolv (phase III study for

Marinomed Biotech AG: Clinical validation of the Marinosolv® platform

Marinomed Biotech AG: Budesolv with a strongly decreased dose of the active ingredient compared to the marketed product Rhinocort Aqua shows pronounced efficacy already after first application – clinical validation of the Marinosolv® platform • Phase III study successfully completed preparing the ground for entering a multi-billion-dollar market • Even after the first application, Budesolv exhibits noticable efficacy • Allergic nasal symptoms markedly reduced within four hours • Six times less active compound than

Go To Page:   1 2 3 4 5 6 7 8 9 10